Organic & Biomolecular Chemistry

Cite this: *Org. Biomol. Chem.*, 2012, **10**, 5253

www.rsc.org/obc

PAPER

Synthetic approaches to a chiral 4-amino-3-hydroxy piperidine with pharmaceutical relevance†

Adrian Ortiz,* Ian S. Young, James R. Sawyer, Yi Hsiao, Amarjit Singh, Masano Sugiyama, R. Michael Corbett, Melissa Chau, Zhongping Shi and David A. Conlon

Received 24th February 2012, Accepted 10th May 2012
DOI: 10.1039/c2ob25411e

Four synthetic strategies were evaluated towards the preparation of (−)-(3*R*,4*R*)-1-benzyl-4-(benzylamino)-piperidin-3-ol (**1**), which was constructed with control over the relative and absolute stereochemistry of the 4,3-amino alcohol moiety. The first strategy employed a novel Rh^{I} catalyzed asymmetric hydrogenation, while two other strategies exploited the existing stereochemistry in 2-deoxy-D-ribose, and the fourth explored both biocatalytic and classical resolution techniques as a means to impart enantioenrichment to racemic intermediates *en route* to targeted structure (−)-**1**.

Introduction

The piperidine **1**[1] is an advanced key intermediate utilized in the synthesis of the investigational new drug candidate, BMS-690514 (**2**, see Fig. 1), developed for treatment of non-small cell lung cancer.[1] An efficient synthesis of **1** from readily available starting materials was required in order to furnish larger quantities of BMS-690514 to support ongoing clinical studies. The initial in-house route used to prepare **1** took advantage of a well-precedented chiral pool based strategy starting from (*R*)-pyroglutamic acid (see Fig. 2).[2] While this strategy was successful in preparing **1** to support initial clinical development, it was lengthy (requiring seven multi-operational steps and three isolations) and was projected to contribute significantly to the overall cost of BMS-690514 (**2**). This complexity led us to pursue an alternative synthesis of **1**. In this article we report on the development and comparison of four alternative strategies towards this valuable intermediate.



Fig. 1 Retrosynthetic analysis of drug substance **2**, and key piperidine **1**.

Results and discussion

Our first strategy sought to employ an asymmetric catalytic method for the installation of the key 4-amino-3-hydroxy moiety. Hydrogenation of keto esters is a powerful tool, providing access to the corresponding hydroxy esters.[3] In our system a *trans*-selective asymmetric hydrogenation would be required from commercially available keto ester **4** (see Scheme 1).[4] The hydrogenation of 2-hydroxycyclohex-1-ene-carboxylic acid, has been reported using Ru-BINAP catalyst with high diastereoselectivity (95 : 5) and enantioselectivity (90% ee),[5] however, this catalyst was not effective for the hydrogenation of compound **4**, giving both low diastereoselectivity (55 : 45) and enantioselectivity (70% ee).

After extensive catalyst screening, [RuCl(cymene)(*R*-C3-tunephos)]Cl **6** (1 mol%) was identified as a suitable catalyst for this transformation. Our optimized conditions for this reaction utilized a hydrogen atmosphere (50 bar, 17 h) in a mixture of EtOAc–MeOH (9 : 1) to yield the desired hydroxy ester **5** as a

Chemical Development, Bristol-Myers Squibb Company, One Squibb Drive, New Brunswick, New Jersey08903, U.S.A.
E-mail: Adrian.Ortiz@bms.com; Tel: +732-227-5816

†Electronic supplementary information (ESI) available: Experimental procedures and characterization data (^{1}H NMR, ^{13}C NMR, HRMS and IR) and copies of ^{1}H NMR and ^{13}C NMR for all new compounds. CCDC 878581 for HCl salt of **24**. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c2ob25411e



Fig. 2 Retrosynthetic analysis of **1** from initial pyroglutamic route.



Scheme 1 Preparation of **5** by asymmetric hydrogenation.

94 : 6 *trans* : *cis* mixture and in 94% ee. The crude product **5** was saponified and isolated as its sodium salt (**7**, NaOTMS, THF, 87% over the two steps, see Scheme 2). Curtius rearrangement (DPPA, *t*-BuOH, 80 °C) proceeded smoothly with *in situ* trapping of the intermediate isocyanate, to afford cyclic carbamate **9** (78%). An interesting advantage in the formation of **9** is that the oxazolidinone simplifies the protecting group strategy for the eventual coupling with fragment **3**. Despite the success of the asymmetric reduction approach, we unfortunately encountered difficulties in finding commercial sources to provide ligand **6** and therefore continued to pursue alternative strategies.

The second strategy investigated was based on a literature precedent for the preparation of chiral 3,4-substituted piperidines.[6] The ring expansion of a 2-deoxy-D-ribose derivative was examined as an avenue to access **1** (Scheme 3). Formation of the methyl glycoside **10** (1.25 : 1 mixture of anomers) was conducted at 0 °C (AcCl, MeOH) to minimize competing formation of the hexose sugar (<8%).[7] Subsequent transformation to its



Scheme 2 Synthesis of carbamate derivative **9**.



Scheme 3 Synthesis of **1** in enantiomerically pure form from 2-deoxy-D-ribose.

bis-tosylate derivative (**11**, 83%) yielded a substrate suitable for glycoside exchange, *via* treatment with an excess of benzyl alcohol in the presence of catalytic TsOH, thus providing **12** as a



Scheme 4 Synthesis of epoxide (−)-**19** from 2-deoxy-D-ribose.

1.3 : 1 mixture of anomers. The excess benzyl alcohol was difficult to remove from the product at this stage. Therefore, the crude bis-tosylate **12** was directly subjected to displacement with $BnNH_2$, providing chromatographically separable cascade precursors **13a/b** in 52% combined yield from **11**.[8] Interestingly, the rate of product formation for each anomer (**13a/b**) was different under hydrogenative conditions (H_2, Pd/C); the more polar anomer had a diminished rate for *–O*-Bn removal, resulting in a reduced yield of (−)-**1** (27%). Extended reaction times (4.5 h), significantly increased *–N*-Bn removal. However, the less polar anomer reached greater than 90% conversion in 2 h, to produce compound (−)-**1** in 48% yield, and >99.9% enantiomeric excess. This reaction has not been optimized with respect to hydrogen pressure, catalyst, or acid, and the major by-products are the *–N*-benzyl cleaved compounds and the methyl glycosides of the starting material. Although high quality **1** was prepared using this strategy, the differential reactivity of **13a/b** reduced the attractiveness of this approach.

A third strategy utilizing 2-deoxy-D-ribose as a chiral building block was also explored (Scheme 4). It has previously been reported[6] that the *N*-Boc derivative of **18** could be converted to the corresponding epoxide by treatment with Moffatt's reagent.[9] In our case, the *N*-benzyl substrate had yet to be utilized in such a transformation, and as will be observed (*vide infra*[11]), an *N*-alkyl substituent is required to obtain a high degree of regioselectivity in the epoxide opening with benzylamine. To this end, 2-deoxy-D-ribose was protected as its isopropylidene derivative **15** (2-methoxypropene, PPTS) in 67% yield. Reduction of **15** ($LiAlH_4$) afforded the corresponding diol, which after conversion to the bis-mesylate **16** (82%, 2 steps), was displaced with benzylamine to give piperidine **17** (93%). The isopropylidene moiety was cleaved under acidic conditions (aq. HCl) to furnish



Scheme 5 Synthesis of racemic (±)-**1** from tetrahydropyridine **20**.

cis-diol **18** (84%). Subsequent treatment with Moffatt's reagent and basic hydrolysis (K_2CO_3, MeOH), resulted in ring closure, and delivered epoxide (−)-**19** in 26% yield and >99.9% ee. Enantiomerically pure epoxide (−)-**19** required only regioselective opening with benzylamine to complete the synthesis of **1** (see Scheme 5).[10] Despite the perceived advantages of using 2-deoxy-D-ribose to prepare **1**, this route suffered from unattractive low yields.

The final strategy towards **1** focused on the development of a simple racemic synthesis to epoxide **19** as a key intermediate. We hoped to take advantage of a recent report detailing the highly regioselective opening of 3,4-epoxy piperidines by nitrogen nucleophiles in the presence of lithium salts.[11] This report thus rendered regioselectivity a non-issue, and left enantioenrichment *via* resolution as the key step still requiring development. The synthesis of **1** began with epoxidation of *N*-benzyl 1,2,5,6-tetrahydropyridine (**20**, see Scheme 5) utilizing a two-step procedure (TFA–H_2O then NCS),[12] to circumvent potential *N*-oxide formation. Thus, the regioisomeric chlorohydrins were treated with base (K_2CO_3, MeOH) to provide racemic epoxide **19**. The 3,4-epoxy piperidine **19** was isolated as its fumaric acid salt **21** in high yield, 73% (from **20**). A salt break (aq. KOH) followed by Li^+-mediated, regioselective (>20 : 1) epoxide opening with $BnNH_2$ (LiCl, CH_3CN)[11b] afforded (±)-**1** as a crystalline solid (85%). It has been previously shown[11b] that lithium chelation between both the oxygen and the basic piperidine nitrogen (*i.e.* *N*-Bn rather than *N*-Boc) is required to achieve the desired regioselectivity.

With a simple synthetic strategy to racemic **1** in place, we explored potential avenues for its enantioenrichment. Initially, we focused on the resolution of racemic epoxide (±)-**19**, as resolution earlier in the synthetic sequence had the potential to increase the efficiency of our route. We were encouraged by the work of Grishna and coworkers on the biotransformations of *N*-benzyl 1,2,5,6-tetrahydropyridines to their corresponding *trans*-diol intermediates (*i.e.* **20** → **22**).[13] We therefore, investigated the potential to perform a microbial resolution of racemic epoxide (±)-**19**. A significant screening of microbes was



Scheme 6 Biocatalytic/kinetic resolution of racemic epoxide (+)-**19**.



Scheme 7 Classical resolution of (±)-**1**.

conducted (see Scheme 6)[14] which interestingly, resulted in only the undesired enantiomer [*i.e.* selective hydrolysis of (−)-**19** over (+)-**19**]. The optimized conditions, [yielding (+)-**19**] utilized *Aspergillus niger* SC 16295 to provide selective hydrolysis of (−)-**19** while leaving epoxide (+)-**19** largely intact (49.6% yield, 97.1% ee).[15]

An alternative enantioenrichment strategy focused on a classical resolution of racemic intermediate (±)-**1**. It was discovered, after a high throughput crystallization screen, that treatment of (±)-**1** with R-*O*-acetyl mandelic acid (1.0 eq.)[16] in EtOH (200 proof) generated the desired diastereomeric salt [(+)-**23**] in 41.7% yield and 93.8% ee (Scheme 7). Unambiguous confirmation for the absolute stereochemistry present in **23** was provided by single crystal X-ray crystallographic analysis (see Fig. 3).[17] This final route provided the target structure (**1**) in 26% overall yield, and required only two chemical transformations and a classical resolution.

Conclusion

In summary, four strategies have been demonstrated on lab scale with the potential to prepare benzyl-protected piperidine **1** in enantiomerically pure form. Each route is characterized by apparent advantages and limitations, and exploits differing strategies for achieving enantioenrichment. A preliminary evaluation of these four routes was conducted in terms of safety, cost, ease of intermediate isolation, availability of starting material, and overall yield, with the final route, employing a classical resolution, being selected for further optimization. The implementation of this route on a kilogram scale is currently under investigation in our laboratories and will be reported in due course.



Fig. 3 X-ray derived ORTEP of bis-HCl salt **24**.

Acknowledgements

We would like to thank Dr Qi Gao for providing X-ray crystallographic analysis of (+)-**24**. We would also like to thank Dr David Kronenthal, Dr Martin Eastgate, and Dr Michael Cassidy for careful review of the manuscript.

Notes and references

1 For Bristol-Myers Squibb patents covering **2** see: (*a*) C. Wei, D. J. Norris, Crystalline forms of (3*R*,4*R*)-4-amino-1-[[4-[(3-methoxyphenyl)-amino]pyrrolo[2,1-F][1,2,4]triazin-5-yl]methyl]piperidine-3-ol. *US Patent* 0191375, August 16, 2007; (*b*) Bristol-Myers Squibb Company, Pyrrolotriazine Compounds as Kinase Inhibitors, *WO Patent* 066176, July 21, 2005; (*c*) Bristol-Myers Squibb Company, Pyrrolotriazine Compounds as Kinase Inhibitors, *US Patent* 7,141,571 B2.
2 N. Langlois and O. Clavez, *Synth. Commun.*, 1998, **28**, 4471; J. K. Thottathil, J. L. Monoit, R. H. Mueller, M. K. Y. Wong and T. P. Kissick, *J. Org. Chem.*, 1986, **51**, 3140.
3 General reviews: R. Noyori, Homogeneous Asymmetric Hydrogenation, in *Asymmetric Catalysis in Organic Synthesis*, John Wiley & Sons, New York, 1994, ch. 2, p. 16. For more recent report; X. Sun, W. Li, G. Hou, L. Zhou and X. Zhang, *Adv. Synth. Catal.*, 2009, **351**, 2553; M. Eggenstein, A. Thomas, J. Theuerkauf, G. Franciò and W. Leitner, *Adv. Synth. Catal.*, 2009, **351**, 725.
4 Z. Guo, B. P. Patel, R. M. Corbett, A. Goswami and R. N. Patel, *Tetrahedron: Asymmetry*, 2006, **17**, 2015.
5 R. Noyori, T. Ikeda, T. Ohkuma, M. Widhalm, M. Kitamura, H. Takaya, S. Akutagawa, N. Sayo and T. Saito, *J. Am. Chem. Soc.*, 1989, **111**, 9134; M. Kitamura, T. Ohkuma, M. Tokunaga and R. Noyori, *Tetrahedron: Asymmetry*, 1990, **1**, 1.
6 D. Wang and W. A. Nugent, *J. Org. Chem.*, 2007, **72**, 7307.
7 O. R. Ludek and V. E. Marquez, *Tetrahedron*, 2009, **65**, 8461.

8 The importance of the benzyl glycoside to initiate the rearrangement under the influence of hydrogen was evident at this stage, as no product was observed if the corresponding methyl glycoside derivative was used (*i.e.* **11**→**1**).
9 S. Greenberg and J. G. Moffatt, *J. Am. Chem. Soc.*, 1973, **95**, 4016.
10 The conversion of **19** to **1** has been established both in this article (see Scheme 5) and previously in the literature (ref. 11*b*).
11 For the regioselective opening of 3,4-epoxy piperidines see: (*a*) I. S. Veselov, I. V. Trushkov, N. S. Zefirov and G. V. Grishina, *Russ. J. Org. Chem.*, 2009, **45**, 1050; (*b*) O. Tokuda, T. Aikawa, T. Ikemoto and I. Kurimoto, *Tetrahedron Lett.*, 2010, **51**, 2832.
12 M. Surkyn, S. F. A. Van Brandt, M. G. C. Verdonck, L. Moens, J. Cuypers and J. R. M. A. Bosmans, *Tetrahedron*, 2008, **64**, 2456.
13 P. B. Terentiev, T. M. Zilberstein, A. A. Borisenko, V. A. Shmorgunov, N. F. Piskunkova and G. V. Grishna, *Chem. Heterocycl. Compd.*, 2003, **39**, 885.
14 See ESI† for a condensed list of the microbes examined.
15 The absolute stereochemistry of (+)-**19** was determined by its conversion to (+)-**1** (LiCl, $BnNH_2$) and then comparison of both chiral HPLC and optical rotation data to that of the known compound. See ESI.†.
16 A high throughput crystallization screen of epoxide (±)-**19** yielded ≤30% ee.
17 Bis-HCl salt **24** (MeOH co-solvate) was serendipitously prepared from (+)-**23** while attempting its recrystallization (from MeOH–CH_2Cl_2) to generate crystals appropriate for single crystal X-ray analysis.